Macter International : Financial Results for the Half Year Ended December 31, 2022
February 20, 2023 at 10:00 am IST
Share
Ref: PSX-23/02
February 20, 2023
The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi
Subject: Financial Results for the half year ended December 31, 2022
مكيلع ملاسلا
We have to inform you that the Board of Directors of our Company in their meeting held on February 18, 2023 at 11:00 am at Karachi recommended the following:
(i) CASH DIVIDEND
An Interim Cash Dividend for the period ended December 31, 2022 at Re. 0.54 per share i.e.5.4%.
(ii)
BONUS SHARES
:
NIL
(iii)
RIGHT SHARES
:
NIL
(iv)
ANY OTHER ENTITLEMENT/CORPORATE ACTION
:
NIL
(v)
ANY OTHER PRICE-SENSITIVE INFORMATION
:
NIL
The financial results of the Company are enclosed herewith.
BOOK CLOSURE NOTICE FOR ENTITLEMENT OF INTERIM CASH DIVIDEND @ 5.4%
The Share Transfer Books of the Company will be closed from March 1, 2023 to March 3, 2023 (both days inclusive) for entitlement of Interim Cash Dividend @ Re. 0.54 per share i.e.5.4%. Physical Transfers/CDS transactions/IDs, received in order at Share Registrar, F.D. Registrar Services (Pvt) Limited, 17th Floor, Saima Trade Tower-A, I. I. Chundrigar Road, Karachi at the close of business on February 28, 2023 will be treated in time for the entitlement of said 5.4% Interim Cash Dividend.
The Half Yearly Report of the Company for the period ended December 31, 2022 will be transmitted through PUCARS separately, within the specified time.
Yours truly,
For and on behalf of
Macter International Limited
Company Secretary
3
MACTER INTERNATIONAL LIMITED
CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE PERIOD ENDED DECEMBER 31, 2022
HALF YEAR ENDED
QUARTER ENDED
DECEMBER 31,
DECEMBER 31,
DECEMBER 31,
DECEMBER 31,
2022
2021
2022
2021
NOTE
........................
(RUPEES IN '000)
Turnover
3,910,667
2,689,832
1,907,607
1,390,294
Cost of sales
(2,292,514)
(1,472,676)
(1,084,106)
(740,420)
Gross profit
1,618,153
1,217,156
823,501
649,874
Distribution costs
(1,046,002)
(803,865)
(560,706)
(419,488)
Administrative expenses
(186,751)
(134,202)
(97,297)
(66,614)
Other expenses
(32,036)
(22,092)
(14,184)
(13,218)
Other income
28,280
20,133
18,086
10,318
(1,236,509)
(940,026)
(654,101)
(489,002)
Operating profit
381,644
277,130
169,400
160,872
Financial charges
11.3 & 14.2
(24,857)
(29,995)
(13,349)
(8,601)
Profit before taxation
356,787
247,135
156,051
152,271
Taxation
17
(129,494)
(69,335)
(57,285)
(37,002)
Net profit for the period
227,293
177,800
98,766
115,269
................. (RUPEES)
(Re-stated)
(Re-stated)
Basic and diluted earnings per share
4.96
4.02
2.16
2.61
The annexed notes from 1 to 21 form an integral part of these consolidated condensed interim financial statements.
Attributable to:
Owner of the Holding Company
231,452
181,241
100,582
116,472
Non- controlling interest
(4,159)
(3,441)
(1,816)
(1,203)
227,293
177,800
98,766
115,269
________________________
______________________
______________________
CHIEF FINANCIAL OFFICER
CHIEF EXECUTIVE
DIRECTOR
Attachments
Original Link
Original Document
Permalink
Disclaimer
Macter International Ltd. published this content on 20 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 February 2023 04:29:05 UTC.
Macter International Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is to manufacture and market pharmaceutical products. The Companyâs business areas are contract manufacturing and branded generic formulations. It is a contract manufacturer for multinational companies, which offers a range of dosage forms: oral solids and liquids, parenteral (ampules and vials), topicals, metered dose inhalers, ear and eye drops. Its contract manufacturing clients include a number of blue-chip multinationals. The Company produces specialty products at its high-tech plant. These include solid and liquid oral dosage forms (tablets, capsules, syrups, suspensions and dry powder), injections (sterile liquid vials, sterile liquid ampoules and sterile dry powders), ointments and creams, drops and inhalers. Its manufacturing operations include formulation, vial filling, lyophilization and packaging of biological drugs.